Please provide your email address to receive an email when new articles are posted on . Varying levels of aerobic and muscle-strengthening activity halved the rates of all-cause and cancer mortality.
Please provide your email address to receive an email when new articles are posted on . The combination of ficlatuzumab and cetuximab extended PFS for patients with pan-refractory recurrent or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback